Cost modeling provides valuable insights to support strategic decision-making when implementing disposable technologies.
Apr 1, 2009
By:
Andrew Sinclair, Miriam Monge
Cost modeling provides valuable insights to support strategic decision-making when implementing disposable technologies.
|
Drug manufacturers should follow a risk-assessment methodology when selecting a single-use mixing system for product development.
Feb 1, 2009
By:
Andrew Sinclair, Miriam Monge
How to choose a disposable mixing system that fits your particular needs.
|
In new disposables projects, it is critical that engineering, procurement, and operations groups work together early on to manage supply chain risk.
Dec 1, 2008
By:
Andrew Sinclair, Miriam Monge
In new disposables projects, it is critical that engineering, procurement, and operations groups work together early on to manage supply chain risk.
|
Can disposables reduce your facility's environmental footprint?
Nov 2, 2008
By:
Andrew Sinclair, Lindsay Leveen, Miriam Monge, Janice Lim, Stacey Cox
Can disposables reduce your facility's environmental footprint? We have compared the environmental footprint of a traditional biopharmaceutical manufacturing facility using fixed-in-place stainless steel equipment, and a facility implementing disposable technologies for cell culture, solution mixing and hold, product hold, and liquid transfer.
|
When a new plant relies heavily on single-use technologies, facility design no longer depends on the process. Instead, other considerations, such as workflows, take center stage.
Aug 1, 2008
By:
Andrew Sinclair, Miriam Monge
In addition to making technical developments, vendors are also looking at ways to improve supply-chain security. By offering standard, off-the-shelf products, vendors are able to shorten lead times and improve the security of supply.
|
To understand the overall cost impact of disposable technologies, it is necessary to build a robust model that covers the entire process.
Jun 1, 2008
By:
Andrew Sinclair
The current focus on cost-of-goods (COGS) models is underplaying the benefits of disposables technology in biopharmaceutical manufacturing. The best method for accounting for the benefits of reduced and delayed capital expenditures is through the use of NPV analysis.
|
Apr 1, 2008
By:
Andrew Sinclair
Disposable technologies that mimic the conventional stainless-steel bioreactor will be most readily adopted
|
The use of disposables has changed significantly in the biopharmaceutical industry.
Feb 1, 2008
By:
Andrew Sinclair
The use of disposables has changed significantly in the biopharmaceutical industry.
|
|
Jul 1, 2007
By:
Claire Hill, Andrew Sinclair
Process development and manufacturing for biopharmaceuticals are often disjointed activities. Disconnects among groups are aggravated by a lack of common terminology and poor data management practices. A UK biotech consortium has initiated a collaborative development effort to address data management issues. The proposed outcome is a data model, based on the ISA-88 Standard for Batch Control, to capture process and facility data throughout the product lifecycle. A data framework that follows the ISA-88 model can simplify process scale up and enable early views of project costs and facility fit.
|
|
